Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Drug Profile

Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Alternative Names: HEAL solution; Mino-Lok Therapy (MLT); Mino-Lok™; Minocycline-EDTA-EtOH

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Leonard Meron Biosciences; University of Texas M. D. Anderson Cancer Center
  • Class Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
  • Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter infections

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 01 Jun 2017 University of Texas M. D. Anderson Cancer Center has a published patent application for enhanced stability of minocycline/disodium edetate/ethyl alcohol in USA
  • 23 Mar 2017 Citius Pharmaceuticals acquires license for minocycline/disodium edetate/ethyl alcohol in South America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top